Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis.
Rheumatology (Oxford)
; 53(8): 1457-64, 2014 Aug.
Article
em En
| MEDLINE
| ID: mdl-24667161
ABSTRACT
OBJECTIVES:
The aim of this study was to assess the efficacy of strontium ranelate in improving symptoms in knee OA.METHODS:
Symptoms were assessed over 3 years in patients with primary knee OA receiving strontium ranelate 2 g/day (n = 454), 1 g/day (n = 445) or placebo (n = 472) in the Strontium Ranelate Efficacy in Knee Osteoarthritis Trial. Clinical response was evaluated using WOMAC subscores, minimal perceptible clinical improvement (MPCI), minimal clinically important improvement (MCII) and a modified OMERACT-Osteoarthritis Research Society International (OARSI) responder definition. Patients who withdrew prematurely from the study were considered non-responders.RESULTS:
There was no significant effect on symptoms for strontium ranelate 1 g/day. At the dosage of 2 g/day, strontium ranelate was associated with greater response than placebo in terms of ≥20% improvement in WOMAC pain from baseline to the last visit (58% vs 47%, P = 0.002) and ≥50% improvement in WOMAC pain (42% vs 36%, P = 0.083). Significant differences were found in MPCI response for WOMAC pain (52% vs 40%, P < 0.001), stiffness (47% vs 39%, P = 0.009) and physical function (46% vs 37%, P = 0.009) and in MCII response for WOMAC physical function (46% vs 37%, P = 0.013). There were also more OMERACT-OARSI-like responders with strontium ranelate (44% vs 35%, P = 0.004). The treatment-placebo difference in MPCI response for WOMAC pain was significant after 6 months (P = 0.024), while that in MPCI and MCII response for WOMAC physical function reached significance after 12 months (P = 0.027 and P = 0.019, respectively).CONCLUSION:
Treatment with strontium ranelate 2 g/day over 3 years is associated with a clinically meaningful improvement in pain from 6 months as well as physical function and stiffness as assessed by the number of responders above thresholds of clinical relevance. TRIAL REGISTRATION Current Controlled Trials. http//www.controlled-trials.com/ (ISRCTN41323372).Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Tiofenos
/
Osteoartrite do Joelho
/
Conservadores da Densidade Óssea
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article